SMMT vs. ELAN, INSM, ROIV, ASND, LEGN, CERE, VKTX, ITCI, JAZZ, and BPMC
Should you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Elanco Animal Health (ELAN), Insmed (INSM), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Summit Therapeutics (NASDAQ:SMMT) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
Summit Therapeutics currently has a consensus target price of $10.50, suggesting a potential upside of 20.90%. Elanco Animal Health has a consensus target price of $18.29, suggesting a potential upside of 3.37%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Elanco Animal Health.
Summit Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -29.83%. Elanco Animal Health's return on equity of 5.98% beat Summit Therapeutics' return on equity.
In the previous week, Summit Therapeutics and Summit Therapeutics both had 16 articles in the media. Elanco Animal Health's average media sentiment score of 0.95 beat Summit Therapeutics' score of 0.64 indicating that Elanco Animal Health is being referred to more favorably in the news media.
Summit Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Summit Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summit Therapeutics has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
Summit Therapeutics received 155 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 57.09% of users gave Summit Therapeutics an outperform vote while only 54.13% of users gave Elanco Animal Health an outperform vote.
Summary
Summit Therapeutics beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.
Get Summit Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SMMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Summit Therapeutics Competitors List
Related Companies and Tools
